DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Blood Screening Market Analysis By Technology, By Product And Segment Forecasts, 2013 - 2024" report to their offering.
The global blood screening market is expected to reach a value of USD 3.9 billion by 2024. The growth of the market is attributed to the increasing screening of donor and continuous technological advancements by the market players. Demand for blood screening tests are increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry.
Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). Result of all these assays must be negative for blood donation.
Technological developments in the market increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Market Variables, Trends & Scope
4 Blood Screening Market Technology Estimates & Trend Analysis
5 Blood Screening Market Product Estimates & Trend Analysis
6 Blood Screening Market Regional Estimates & Trend Analysis
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/r4fdrf/blood_screening